

Report to Board of Directors

For Information

Finance Report April 2021 (Month 1), FY22

Contents

Executive Summary

1. Income Statement
2. Clinical Income
3. Non-Clinical Income
4. Agency
5. Expenditure by Service Line
6. Cost Improvement Plan
7. Statement of Position
8. Cash-flow
9. Working Capital Indicators
10. Capital Investment Programme
11. Reconciliation to NHSI Template

A risk assessment has been undertaken around the legal issues that this paper presents and there are no issues that need to be referred to the Trust Solicitors.

Executive Summary

	Month 1
EBITDA performance	£1.0m surplus, £0.4m adverse to plan
I&E performance	£0.1m surplus, £0.4m adverse to plan
Cost Improvement Plan	£0.1m, £0.1m adverse to plan
Cash	Decrease of £0.2m

- The month 1 I&E position is a **£0.1m** surplus, **£0.4m** adverse to plan. EBITDA is a **£1.0m** surplus, **£0.4m** adverse to plan.
- The FY22 plan is for a breakeven position with a **£3.0m** surplus in the first half of the year and a **£3.0m** deficit in the second half of the year.
- The adverse position is driven by agency and bank spend particularly in the Oxon & BSW MH and Bucks MH directorates and high Out of Area Placements in Oxon & BSW MH directorate.
- CIP savings YTD is **£0.1m**, **£0.1m** adverse to plan due to delay in CIP engagement due to focus being given to Covid.
- The closing cash position at the end of April was **£55.5m**.

Recommendation:

The Board of Directors are asked to note the Finance Report against plan and seek any further assurances as required.

1. Income Statement

INCOME STATEMENT								
YTD Actual M1	Prior Year				Plan	Month 1		
	£m	£m	%			£m	£m	£m
25.0	5.6	22.5%	Clinical Income	29.9	30.7	0.7	2.4%	
6.7	-1.2	-17.4%	Other Operating Income	4.7	5.5	0.8	16.6%	
31.7	4.5	14.1%	Operating Income, Total	34.6	36.2	1.5	4.4%	
22.9	-3.1	-13.5%	Employee Benefit Expenses (Pay)	24.3	26.0	-1.7	-6.9%	
7.7	-1.5	-19.2%	Other Operating Expenses	8.9	9.2	-0.3	-2.8%	
30.6	-4.6	-14.9%	Operating Expenses, Total	33.2	35.2	-1.9	-5.8%	
0.0	0.0	0.0%	Non-Operational Income	0.0	0.0	0.0	0.0%	
1.1	-0.1	-8.9%	EBITDA	1.4	1.0	-0.4	-29.1%	
0.0	0.0	0.0%	Profit/(Loss) on asset disposal	0.0	0.0	0.0	0.0%	
0.6	0.0	0.0%	Depreciation and Amortisation	0.5	0.6	-0.1	-16.2%	
0.0	0.0	0.0%	Asset Impairment	0.0	0.0	0.0	0.0%	
0.1	0.0	0.0%	Interest	0.1	0.1	0.0	5.5%	
0.1	0.0	0.0%	Other Finance Charge	0.1	0.1	0.0	0.0%	
0.3	0.2	60.8%	PDC Dividend	0.2	0.2	0.1	29.7%	
0.0	0.1	81771.6%	Surplus/ (Deficit)	0.5	0.1	-0.4	-82.5%	

The month 1 I&E position is a **£0.1m** surplus, **£0.4m** adverse to plan. EBITDA is a **£1.0m** surplus, **£0.4m** adverse to plan.

The FY22 plan is for a breakeven position with a **£3.0m** surplus in the first half of the year and a **£3.0m** deficit in the second half of the year.

The adverse position is driven by agency and bank spend particularly in the Oxon & BSW MH and Bucks MH directorates and high Out of Area Placements in Oxon & BSW MH directorate

Budgets have not yet been set for mental health new investment funding and income and expenditure for these are not reflected in the month 1 position. However, the planned contribution from these investments is accrued for in the month 1 position.

The I&E performance in FY22 is **£0.1m** better than in FY21. The financial regime in the first 6 months of FY21 was to report a breakeven position with a retrospective top-up payment to cover Covid-19 costs. (For FY22 there is a fixed expenditure allowance for Covid cost recovery.)

Breakdown of Covid-19 Costs

NHSI/E category	Expanding		Plans to release		Existing workforce	Covid-19 virus	After Care and	Segregation of	Total
	£'000s	workforce	bed capacity	Decontamination					
Employee Benefits (Pay)	760				14	26		13	812
Other Operating Expenses			216	3		- 45	97	16	287
Total	760		216	3	14	- 19	97	28	1,099

The Trust is receiving an allocation of **£11,164k** for the first 6 months of the year (**£1,861k** per month) to cover costs associated with Covid-19. Planning assumptions assume a underspend of **£1,196k (£199k per month)** on this Covid allocation to meet the plan for the first half of the year. The spend in month 1 was **£1,099k, £762k** below the funding.

The Covid-19 costs incurred in month 1 as per the NHSE/I categories were:

- Expanding workforce **£760k** – additional bank and agency staff, agency housekeepers, costs associated with the 24/7 Mental Health Helpline, additional costs in the GP Out of Hours service, and other increased staff costs to create additional capacity
- Plans to release bed capacity **£216k** – block contract for Mental Health independent sector beds to create bed capacity as a result of keeping occupancy on mental health wards at 85% to assist with Covid-19 control measures
- Decontamination **£3k** – minor Estates works
- Existing Workforce additional shifts **£14k** – spend on staff working additional hours
- Covid-19 virus testing **£19k** – supplies and additional staffing for the staff testing team. Costs were over-estimated for this in FY21 by finance which is why there is a negative non-pay cost in M1.
- After Care and Support costs **£97k** – mainly the cost of providing food to staff
- Segregation of patient pathways **£28k** –the costs of the PPE Warehouse

In addition to these costs the Trust is also incurring costs for running 3 mass vaccination centres and the payments made to final year nursing students for which retrospective top-up payments are received from NHSE/I based on the costs incurred.

These costs in month 1 were:

- Payments to final year students **£78k**
- Covid-19 vaccination centres **£1,022k**

	Plan YTD M1	Actual YTD	Variance		Actual YTD	Change	
	FY22	M1 FY22	£'000	%	M1 FY21	£'000	%
Block	25,939	26,744	805	3%	21,096	5,648	27%
Cost & Volume	1,040	1,062	22	2%	1,056	5	1%
Cost Per Case	492	449	-43	-9%	365	84	23%
CQUIN	239	239	0	0%	222	17	7%
Local Authority	1,757	1,695	-62	-4%	1,819	-125	-7%
Section 75 (pooled budget)	450	452	2	1%	449	3	1%
Private Patients	5	11	6	121%	5	5	96%
Clinical Income Total	29,921	30,651	730	2%	25,013	5,638	23%
Education And Training	1,203	1,278	76	6%	1,233	45	4%
Research & Development	1,067	1,206	139	13%	485	721	149%
FRF/Top Up Payment	0	1,100	1,100		3,117	-2,016	-65%
Accommodation	77	49	-28	-36%	81	-32	-39%
Catering	0	0	0	0%	0	0	0%
Non-Patient Care to Other Bodies	101	128	27	26%	151	-23	-15%
Other Income	120	-89	-209	-174%	123	-212	-172%
Parking	6	0	-6	-100%	0	0	-100%
Oxford Pharmacy Sales	2,144	1,828	-316	-15%	1,475	353	24%
Other Operating Income Total	4,718	5,501	783	17%	6,665	-1,164	-17%
Permanent	23,312	19,924	3,388	15%	18,478	-1,446	-8%
Flexible	550	1,897	-1,347	-245%	1,837	-60	-3%
Agency	471	4,180	-3,709	-787%	2,596	-1,584	-61%
Employee Benefits Expenses	24,333	26,001	-1,668	-7%	22,910	-3,091	13%
Clinical Services & Supplies	2,740	2,129	611	22%	1,567	-562	36%
Drugs	2,285	2,005	280	12%	1,730	-275	16%
PFI	49	32	17	35%	53	21	-40%
Car Park Security	0	0	0		0	0	
Premises And Fixed Plant	1,139	1,099	41	4%	1,369	270	-20%
Premises - Business Rates	113	123	-9	-8%	84	-38	45%
Secondary Commissioning	926	2,012	-1,086	-117%	926	-1,087	117%
Establishment Expenditure	604	439	165	27%	870	431	-50%
Insurance	24	45	-22	-91%	17	-28	162%
Audit Fees External	7	5	3	35%	5	0	0%
Audit Fees Internal	8	4	4	49%	9	4	-52%
Clinical Negligence	56	83	-27	-49%	69	-14	20%
Consultancy	6	-20	26	465%	1	21	-3803%
General Supplies And Services	378	270	108	29%	199	-71	36%
Legal Fees	19	24	-5	-28%	21	-3	14%
Losses And Special Payments	2	1	1	57%	1	0	-38%
NHS Services	131	97	33	26%	120	22	-19%
Other Non-Pay Expenditure	-157	447	-603	-385%	320	-127	40%
Other Services	47	20	28	58%	44	24	-55%
Patient Travel	0	0	0	0%	0	0	0%
Provisions	5	46	-42	-883%	6	0	0%
Redundancy Costs	0	0	0		0	0	0%
Training & Conferences	140	92	48	34%	53	-40	75%
Transport - Business Travel	315	150	165	52%	199	49	-25%
Transport - Other	68	54	14	20%	54	0	-1%
Total Other Operating Expenses	8,904	9,157	-253	-3%	7,717	-1,400	18%
EBITDA Total	1,402	994	-408	-29%	1,051	-57	-5%

Performance against Plan

EBITDA is a **£1.0m** surplus, **£0.4m** adverse to plan at month 1 The main drivers of the position are:

1. Block Income **£0.8m** favourable – due to contribution from additional investment for which budget has not been set (**£0.5m**), additional income for the risk share in Childrens Continuing Healthcare (**£0.1m**) plus other small variances.
2. FRF/Top up Payment **£1.1m** favourable – this is the retrospective top up payments for Covid-19 costs which are not part of the Covid-19 allocation. **£1.0m** is for the costs of running the vaccination sites and **£0.1m** is to cover the costs of paid final year students.
3. Employee Benefits Expenses (Pay) **£1.7m** adverse - **£0.9m** of this is due to staff at the mass vaccination centres and **£0.1m** is due to paid final year students. Budgets have not been set for these but the costs are covered by additional income received. Other significant adverse variances include Oxfordshire & BSW MH (**£0.8m**), Buckinghamshire MH (**£0.3m**) and Community (**£0.3m**) – all driven by bank and agency spend. These are offset by a £0.3m favourable variance for investment budget that needs to be allocated to services and a net favourable variance of **£0.4m** across other services.
4. Clinical Services & Supplies **£0.6m** favourable - **£1.0m** is due to a category change with Secondary Commissioning costs offset with various small variances in other services.
5. Secondary Commissioning **£1.1m** adverse – **£1.0m** is due to a category change with Clinical Services & Supplies and £0.1m is due to an overspend on Oxfordshire OATs.
6. Other Non-Pay Expenditure **£0.6m** adverse – this reflects the current risk in budgets but further budget adjustments are required for new investment funding which will eliminate this variance.


Performance against Prior Year

The EBITDA position is **£0.1m** worse than last financial year. The significant changes from FY21 are:

1. Block income is **£5.6m** higher than last year due to Covid funding now being reported as block income rather than FRF income (**£1.8m**), income for the CAMHS Provider Collaborative (**£1.3m**), income for Residential Social Care previously categorised as local authority income (**£0.3m**), investment in BSW CAMHS services (**£0.2m**), additional income for the Forensic New Care Model (**£0.7m**), additional income in the Bucks continuing healthcare service (**£0.2m**), additional income in Children's Continuing Healthcare (**£0.1m**), new funding for the Ageing Well programme (**£0.1m**), **£0.7m** due to MHIS funding in mental health services and **£0.2m** across other services.
2. Research & Development income is **£0.7m** higher than last year due to additional grant and study income.
3. FRF/Top Up Payment is **£0.2m** lower than last year. The Covid-19 allocation and top up payments were reported in this category last year but they are now in clinical income. The income reported in this category this year is to cover the costs of the mass vaccination sites and paid final year students.
4. Permanent staff costs have increased by **£1.4m** from last year, due to **£0.7m** new costs in Oxfordshire & BSW MH and Buckinghamshire MH directorates as a result of investment in these services last year, **£0.3m** costs for Covid-19 as a result of not recording Covid-19 costs fully at month 1 last year, **£0.3m** increased costs in Research & Development and **£0.1m** across other services.
5. Agency staff costs have increased by **£1.6m** from last year, of which **£0.8m** is attributable to the Covid-19 mass vaccination centres, **£0.2m** costs for Covid-19 as a result of not recording Covid-19 costs fully at month 1 last year with the remaining £0.6m increase across multiple services.
6. Clinical Service & Supplies are **£0.6m** higher than last year due to **£1.2m** payments to other providers as part of the CAMHS Provider Collaborative, a **£0.2m** increase in subcontracted costs in Talking Space, offset with a **£1.0m** due to a category change with Secondary Commissioning costs. The remaining difference is across various other services.
7. Secondary Commissioning costs are **£1.1m** higher than last year due to a category change with Secondary Commissioning costs.

Out of Area Treatments (OATs)

OATs are **£0.1m** overspent at month 1 (**£177k** overspend in Oxfordshire offset with a **£53k** underspend in Buckinghamshire). This excludes the costs of a 16 bed contract with Elysium which is reported under Covid-19 costs. This is a further spend of **£0.3m**. Infection Control guidelines are currently that Mental Health wards should operate at 85% capacity and until these guidelines change the OATs costs are unlikely to reduce.



Variance to Plan by Month

PLAN		Month 1	
			£m
Clinical Income			25.8
Other Operating Income			5.1
Operating Income Total			31.0
Employee Benefits Expenses			21.8
Other Operating Costs			8.1
Operating Expenses Total			29.9
EBITDA			1.1
ACTUAL			
			Month 1
			£m
Clinical Income			25.0
Other Operating Income			6.7
Operating Income Total			31.7
Employee Benefits Expenses			22.9
Other Operating Costs			7.7
Operating Expenses Total			30.6
EBITDA			1.1
VARIANCE			
			Month 1
			£m
Clinical Income	-		0.8
Other Operating Income			1.6
Operating Income Total			0.7
Employee Benefits Expenses	-		1.1
Other Operating Costs			0.3
Operating Expenses Total	-		0.8
EBITDA	-		0.0

2. Clinical Income

CLINICAL INCOME	YTD at month 1			
	Plan £'000	Actual £'000	Variance £'000	Variance %
Any Qualified Provider	284	284	(0)	0%
Bath & NE Somerset Block	0	20	20	0%
Berkshire Block	16	16	(0)	0%
Buckinghamshire Block	3,896	3,877	(19)	0%
Buckinghamshire Block - IAPT	0	0	0	0%
Buckinghamshire County Council	710	694	(16)	-2%
Buckinghamshire S75 (pooled budget)	299	302	2	1%
Cost per Case Income	202	161	(40)	-20%
CQUIN provision	0	0	0	0%
Department of Health & Social Care	0	0	0	100%
Income from NHS Trusts	157	11	(146)	-93% ①
Nene Block	0	0	0	0%
NHS BSW	890	932	42	5%
NHS England Block	5,624	5,636	12	0%
NHS England Cost & Volume	46	46	0	0%
NHS England New Care Models	0	15	15	0%
NHS England FCAMHS	91	91	0	0%
NHS Northamptonshire	78	69	(8)	-11%
Other CCGs Income	234	584	349	149% ②
Other Local Authority	4	10	6	164%
Oxfordshire Block - IAPT	522	546	23	4%
Oxfordshire Block - Learning Disabilities	575	575	(0)	0%
Oxfordshire Block - main contract	9,518	9,962	445	5% ③
Oxfordshire Block - OBC	4,045	4,117	71	2%
Oxfordshire Block - CAMHS	823	846	22	3%
Oxfordshire Cost & Volume	602	624	22	4%
Oxfordshire County Council	1,001	948	(53)	-5%
Oxfordshire S75 (pooled budget)	150	150	0	0%
Personal Injury Compensation	9	7	(2)	-25%
Private Patients	5	11	6	121%
Swindon Block	0	0	0	0%
Wales Cost & Volume	75	75	0	0%
Wiltshire Block	21	0	(21)	-100%
Wiltshire Borough Council	43	43	0	0%
Clinical Income Total	29,921	30,651	730	2%

Clinical income is **£730k** favourable to plan at month 1. Material variances to the plan are:


1. Income from NHS Trusts **£146k** adverse – this is due to a coding error of the budget which will be corrected for month 2
2. Other CCGs income **£349k** favourable – due to additional income for which budget has not yet been set
3. Oxfordshire Block – main contract **£445k** favourable – due to contribution from investment funding for which budget has not yet been set (**£266k**) and additional income for the risk share in Childrens Continuing Healthcare (**£134k**), plus other small variances.

3. Non-Clinical Income

NON-CLINICAL INCOME	YTD at month 1			
	Plan £'000	Actual £'000	Variance £'000	Variance %
Education & Training	1,203	1,278	76	6%
Other Operating Income	2,449	3,017	568	23%
Research & Development	1,067	1,206	139	13%
Non- Clinical Income Total	4,718	5,501	783	17%

- Education & Training income **£76k** favourable. Budgets need to be revised to reflect the actual income being received.
- Other Operating Income **£568k** favourable due to retrospective top up payments for the costs of the mass vaccination centres (**£1,022k**) and payments to final year students (**£78k**), offset with lower than planned sales in Oxford Pharmacy Store (**£315k**) and a reduction in income for national clinical excellence awards (offset with costs) (**£225k**) and a net favourable variance of **£8k** across other services.
- Research & Development income is **£139k** favourable due to additional income for which budgets have not yet been set.

4. Agency



Due to the late planning process for FY22 the Trust's agency plan with NHSE/I has not yet been set.

At month 1 **£4.2m** has been spent on agency staff, which is **16.0%** of total staff costs. This includes **£0.8m** of agency spend in the Covid-19 vaccination centres and **£0.3m** as a result of Covid-19. Note that the graphs above exclude spend in the Covid-19 vaccination centres to show a normalised position.

Please refer to the HR report for further details.

6. Cost Improvement Plan

PIP (CIP) Delivery at month 01 FY22						
Project	YTD Plan	YTD Actual	YTD Variance	Full Year Plan	Forecast	Forecast Variance
	£'000	£'000	£'000	£'000	£'000	£'000
Agency Direct Engagement	0	0	0	216	0	-216
Non Pay Expenditure	141	141	0	1,694	1,694	0
Agency Reduction - improved recruitment	85	0	-85	1,619	0	-1,619
Total	226	141	-85	3,529	1,694	-1,835

- The FY22 CIP Target is **£3.5m** phased **£1.3m** in H1 and **£2.2m** in H2. The target represents 0.9% of turnover which is less than pre-Covid.
- The savings as at the end of month 1 are **£0.1m** arising from reduction in non-pay expenditure such as business miles and room hire costs. It is assumed that this scheme will continue to deliver to plan, **£1.7m**.
- The YTD and forecast savings are **£0.1m** & **£1.8m** adverse to plan respectively. The primary reason for this is delay in CIP engagement due to Covid.

7. Statement of Financial Position

Statement of Financial Position as at 30th April 2021

31 March 2021		Month 12 FY21	Month 1 FY22	Movement	
£'000		£'000	£'000	Year to date	In month
				£'000	£'000
	Non-current assets				
4,359	Intangible Assets	4,359	4,072	(287)	(287)
145,308	Property, plant and equipment	145,308	144,863	(445)	(445)
187	Trade and other receivables	187	187	0	0
149,854	Total non-current assets	149,854	149,122	(732)	(732)
	Current Assets				
1,609	Inventories	1,609	2,122	513	513
13,480	Trade and other receivables	13,480	13,665	185	185
	Non-current assets held for sale		0	0	0
55,697	Cash and cash equivalents	55,697	55,513	(184)	(184)
70,786	Total current assets	70,786	71,300	514	514
	Current Liabilities				
(54,258)	Trade and other payables	(54,258)	(48,188)	6,070	6,070
(1,919)	Borrowings	(1,919)	(1,976)	(57)	(57)
(1,968)	Other financial liabilities	(1,968)	(1,968)	0	0
(1,741)	Provisions	(1,741)	(1,540)	201	201
(9,687)	Deferred income	(9,687)	(15,440)	(5,753)	(5,753)
(69,573)	Total Current Liabilities	(69,573)	(69,112)	461	461
	Non-current Liabilities				
	Trade and other payables		0	0	0
(17,723)	Borrowings	(17,723)	(17,677)	46	46
(3,868)	Provisions	(3,868)	(4,068)	(200)	(200)
(1,351)	Other Liabilities	(1,351)	(1,351)	0	0
(22,942)	Total non-current liabilities	(22,942)	(23,096)	(154)	(154)
128,125	Total assets employed	128,125	128,213	88	88
	Financed by (taxpayers' equity)				
99,119	Public Dividend Capital	99,119	99,120	1	1
19,180	Revaluation reserve	19,180	19,150	(30)	(30)
	Other reserves		0	0	0
9,827	Income & expenditure reserve	9,827	9,943	117	117
128,125	Total taxpayers' equity	128,125	128,213	88	88

1. Non-current assets have decreased by **£0.7m** in-month. This is largely due to the in-month depreciation charge.
2. Trade and other receivables have increased by **£0.2m** in month in line with net cash inflows.
3. There has been no significant change in the cash position in month.
4. Trade and other payables have decreased by **£6m** in the month. The decrease is in line with the net cash outflows.
5. Deferred income has increased by **£5.7m** in year to **£15.4m**
6. Borrowings have decreased by **£46k** in the month in line with the expected decrease in the Trust's PFI liability.
7. The **£0.1m** in-year increase in the I&E reserve reflects the Trust's reported surplus in month.

8. Cash Flow


STATEMENT OF YEAR TO DATE CASH FLOWS

	Month 1 FY22 Actual £'000
Cash flows from operating activities	
Operating surplus/(deficit) from continuing operations	396
Operating surplus/(deficit) from discontinuing operations	0
Operating surplus/(deficit)	396
Non-cash income and expense:	
Depreciation and amortisation	598
Impairments and profit on disposal of assets	0
(Increase)/Decrease in Trade and Other Receivables	(315)
(Increase)/Decrease in Inventories	(513)
Increase/(Decrease) in Trade and Other Payables	(4,360)
Increase/(Decrease) in Deferred Income	5,753
Increase/(Decrease) in Provisions	(1)
Other Movements in Operating Cashflows	0
NET CASH GENERATED FROM/(USED IN) OPERATIONS	1,559
Cash flows from investing activities	
Interest received	2
Purchase of Non Current Assets	(1,744)
Sale of PPE	0
Net cash generated from/(used in) investing activities	(1,742)
Cash flows from financing activities	
Public dividend Capital Received	0
Loans received	0
Loans repaid	0
Capital element of lease rental payments	0
Capital element of Private Finance Initiative Obligations	0
Interest paid	0
Interest element on leases	0
Interest element of Private Finance Initiative obligations	0
PDC Dividend paid	0
Net cash generated from/(used in) financing activities	0
Increase/(decrease) in cash and cash equivalents	(184)
Cash and Cash equivalents at 1st April	55,697
Cash and Cash equivalents at 30th April	55,513







Summary Notes

- The cash flow movements are consistent with the comments made on the Statement of Financial Position.
- The closing cash position at Month 1 was **£55.5m**.

FIC Cashflow Forecast



9. Working Capital Indicators

Working Capital Ratios			
Ratio	Target	Actual	Risk Status
Debtor Days	30	43	
Debtors % > 90 days	5.0%	15.4%	
Creditor Days	30	39	
BPPC NHS - Value of Inv's pd within target (ytd)	95.0%	86.9%	
BPPC Non-NHS - Value of Inv's pd within target (ytd)	95.0%	91.2%	
Cash (£m)	38.0	55.5	

Summary Notes

- Debtor days at month 1 below target.
- Debtors % over 90 days below target due to overdue invoices: NHSE FY20 NCM Inv £690k, Ox CCG £495k
- The Creditor days position is below plan due to high level of accruals for NHS and Non-NHS suppliers and the impact of the BPPC figures.
- NHS BPPC is below target.
- Non-NHS BPPC is marginally below target.
- Cash is better than target, as outlined in section 7 and 8.

10. Capital Investment Programme

CAPITAL PLAN FY22		External Funding (£000)	Internal Funding (£000)			
Description	Plan	PDC	PDC Received	PFI / Other	ICS Internal Cash	Comments
Already Committed	2,599,000		823,000		1,776,000	Estate
Estates - Compliance works	1,580,000				1,580,000	Estates - Compliance works
Requests from Services						
OSWB	700,000				700,000	Estate
BUCKS	300,000				300,000	Estate
SPEC - LD	-					
SPEC - Forensic	760,000				760,000	Estate
SPEC - Dental	500,000				500,000	Estate
COMMUNITY	675,000				675,000	Estate
SUSTAINABILITY	186,000				186,000	Estate
PFI / CAMS / Others	125,000		36,000	89,000		
IT	2,007,000				2,007,000	FY22 IT
BOB / ICS Budget Total	9,432,000	-	859,000	89,000	8,484,000	
PICU FY22 PDC	2,977,000	2,977,000				PICU PDC
Subtotal	12,409,000	2,977,000	859,000	89,000	8,484,000	

- The FY22 draft capital plan totals **£12.4m** (subject to final agreement with the ICS). The detailed capital plan is currently at the approval stage with the CPSC and Exec's.